Udai Banerji, MD, discusses the results from a phase 1 trial with the combination of VS-6766 (CH5126766) and defactinib in KRAS-mutant tumors.
Udai Banerji, MD
Advertisement
Articles by Udai Banerji, MD
Advertisement
Latest Updated Articles
Dr. Banerji on the Clinical Activity of VS-6766/Defactinib in KRAS-Mutant TumorsPublished: May 8th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
3
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
4
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
5